# A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

> **NCT05458219** · PHASE1 · RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 470 (estimated)

## Conditions studied

- Locally Advanced Unresectable or Metastatic Solid Tumors

## Interventions

- **DRUG:** IBI343
- **DRUG:** FOLFIRINOX/mFOLFIRINOX
- **DRUG:** mFOLFOX
- **DRUG:** IBI343

## Key facts

- **NCT ID:** NCT05458219
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-26
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 470 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05458219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05458219, "A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05458219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*